Jack Nielsen - Nov 9, 2021 Form 4 Insider Report for IO Biotech, Inc. (IOBT)

Role
Director
Signature
/s/ Brian Burkavage, Attorney-in-Fact for Jack B. Nielsen
Stock symbol
IOBT
Transactions as of
Nov 9, 2021
Transactions value $
$9,100,000
Form type
4
Date filed
11/12/2021, 03:15 PM
Previous filing
Nov 4, 2021
Next filing
Mar 21, 2022

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction IOBT Common Stock Conversion of derivative security +2.37M 2.37M Nov 9, 2021 See footnote F1, F2
transaction IOBT Common Stock Purchase $9.1M +650K +27.48% $14.00* 3.02M Nov 9, 2021 See footnote F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction IOBT Series C Preferred Stock Conversion of derivative security $0 -188K -100% $0.00* 0 Nov 9, 2021 Common Stock 2.37M See footnote F1, F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Upon the closing of the Issuer's initial public offering, each share of Series C Preferred Stock beneficially owned by the reporting person automatically converted, for no additional consideration, into the number of shares of Common Stock reported in Column 7 of Table II. These shares of Series C Preferred Stock had no expiration date.
F2 The securities are held by Vivo Capital Fund IX, L.P. ("Fund IX"). Vivo Capital IX, LLC ("Capital IX") is the general partner of Fund IX. The reporting person is a managing member of Capital IX and may be deemed to share voting and investment power with respect to the shares beneficially owned by Fund IX and disclaims Section 16 beneficial ownership of such securities held by Fund IX, except to the extent of his pecuniary interest therein, if any.